乾癬治療薬の世界市場予測・分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.2 Symptoms 28
4 Epidemiology 30
4.1 Disease Background 30
4.2 Risk Factors and Comorbidities 30
4.3 Global Trends 31
4.3.1 Prevalence 31
4.4 Forecast Methodology 33
4.4.1 Sources Used for One-Year Diagnosed Prevalence of Psoriasis 35
4.4.2 Sources Not Used 37
4.4.3 Forecast Assumptions and Methods, One-Year Diagnosed Prevalent Cases of Psoriasis 38
4.5 Epidemiological Forecast for Psoriasis (2014-2024) 40
4.5.1 One-Year Diagnosed Prevalent Cases of Psoriasis 40
4.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis 42
4.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis 44
4.5.4 Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis 46
4.5.5 One-Year Diagnosed Prevalent Cases of Psoriasis by Severity 47
4.6 Discussion 48
4.6.1 Epidemiological Forecast Insight 48
4.6.2 Limitations of the Analysis 49
4.6.3 Strengths of the Analysis 49
5 Disease Management 50
5.1 Diagnosis and Treatment Overview 50
5.1.1 Diagnosis 50
5.1.2 Leading Prescribed Drugs and Treatment Guidelines 51
5.1.3 Clinical Practice 54
5.2 US 54
5.3 5EU 59
5.4 Japan 62
5.5 India 65
6 Competitive Assessment 67
6.1 Overview 67
6.2 Strategic Competitor Assessment 68
6.3 Product Profiles – Major Brands 69
6.3.1 Enbrel (Etanercept) 69
6.3.2 Humira (Adalimumab) 76
6.3.3 Remicade (Infliximab) 82
6.3.4 Stelara (Ustekinumab) 89
6.3.5 Cosentyx (Secukinumab) 95
6.3.6 Taltz (Ixekizumab) 103
6.3.7 Otezla (Apremilast) 112
6.3.8 Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate) 117
6.3.9 Methotrexate 123
6.3.10 Fumaderm (Fumaric Acid Esters) 128
6.3.11 Alzumab (Itolizumab) 133
6.3.12 Other Therapeutic Drug Classes Used in Psoriasis 136
6.3.13 Non-pharmacological Therapy 137
7 Unmet Need and Opportunity 140
7.1 Overview 140
7.2 Limited Patient Access Due to Drug Reimbursement Pattern 140
7.2.1 Unmet Need 140
7.2.2 Gap Analysis 141
7.2.3 Opportunity 142
7.3 Improved Drug Safety and Efficacy Profiles 142
7.3.1 Unmet Need 142
7.3.2 Gap Analysis 143
7.3.3 Opportunity 143
7.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 144
7.4.1 Unmet Need 144
7.4.2 Gap Analysis 145
7.4.3 Opportunity 145
7.5 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 146
7.5.1 Unmet Need 146
7.5.2 Gap Analysis 146
7.5.3 Opportunity 147
8 Pipeline Assessment 148
8.1 Overview 148
8.2 Clinical Trial Mapping 149
8.2.1 Clinical Trials by Country 149
8.3 Clinical Trials by Phase and Trial Status 150
8.4 Promising Drugs in Clinical Development 151
8.4.1 Xeljanz (Tofacitinib) 153
8.4.2 Brodalumab 160
8.4.3 Guselkumab (CNTO-1959) 168
8.4.4 Tildrakizumab 173
8.4.5 Piclidenoson (CF-101) 180
8.4.6 Additional Phase III Pipeline Products 185
8.4.7 Phase II Pipeline Products 185
8.4.8 Phase I Pipeline Products 187
8.5 Biosimilar Pipeline Products 188
8.5.1 Introduction 188
8.5.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 189
8.5.3 Biosimilars in the Immunology Community 189
8.5.4 By the Numbers: Biosimilars in Development 190
8.5.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 194
8.5.6 Uptake of Biosimilars for Psoriasis is Expected to Vary by Market 195
8.5.7 Biosimilars Forecast 197
9 Current and Future Players 202
9.1 Overview 202
9.2 Trends in Corporate Strategy 205
9.3 Company Profiles 207
9.3.1 Johnson & Johnson 207
9.3.2 AbbVie 209
9.3.3 Amgen 211
9.3.4 Novartis 213
9.3.5 Pfizer 216
9.3.6 Eli Lilly 217
9.3.7 Merck 219
9.3.8 LEO Pharma 221
9.3.9 Celgene 224
9.3.10 Can-Fite Biopharma 225
10 Market Outlook 228
10.1 Global Markets 228
10.1.1 Forecast 228
10.1.2 Drivers and Barriers – Global Issues 233
10.2 US 236
10.2.1 Forecast 236
10.2.2 Key Events 242
10.2.3 Drivers and Barriers 242
10.3 5EU 244
10.3.1 Forecast 244
10.3.2 Key Events 250
10.3.3 Drivers and Barriers 250
10.4 Japan 252
10.4.1 Forecast 252
10.4.2 Key Events 256
10.4.3 Drivers and Barriers 256
10.5 India 258
10.5.1 Forecast 258
10.5.2 Key Events 261
10.5.3 Drivers and Barriers 261
11 Appendix 264
11.1 Bibliography 264
11.2 Abbreviations 281
11.3 Methodology 286
11.4 Forecasting Methodology 286
11.4.1 Diagnosed Psoriasis Patients 286
11.4.2 Percent Drug-Treated Patients 287
11.4.3 Drugs Included in Each Therapeutic Class 287
11.4.4 Launch and Patent Expiry Dates 288
11.4.5 General Pricing Assumptions 289
11.4.6 Individual Drug Assumptions 290
11.4.7 Generic Erosion 298
11.4.8 Pricing of Pipeline agents 298
11.5 Physicians and Specialists Included in this Study 299
11.6 Primary Research – Prescriber Survey 302
11.7 About the Authors 303
11.7.1 Author 303
11.7.2 Reviewer 303
11.7.3 Epidemiologist 304
11.7.4 Global Director of Therapy Analysis and Epidemiology 304
11.7.5 Global Head of Healthcare 305
11.8 About GlobalData 306
11.9 Disclaimer 306